Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| GD8-C5243 | Cynomolgus | Cynomolgus Latent GDF-8 Protein, His Tag |  |
|
|
| GD8-M5243 | Mouse | Mouse latent GDF-8 Protein, His Tag |  |
|
|
| GD8-M82Q3 | Mouse | Biotinylated Mouse latent GDF-8 Protein, Avitag™,His Tag |  |
|
|
| GD8-H82Q3 | Human | Biotinylated Human latent GDF-8 Protein, His,Avitag™ |  |
|
|
| GD8-H8243 | Human | Biotinylated Human latent GDF-8 Protein, His Tag, ultra sensitivity (primary amine labeling) (MALS & SPR verified) |  |
|
|
| GD8-H5343 | Human | Human latent GDF-8 Protein, His Tag (MALS verified) |
|
|
|
| GD8-H5243 | Human | Human latent GDF-8 Protein, His Tag (pro & latent) (MALS verified) |  |
|
|
Human Follistatin Protein, His Tag, premium grade (Cat. No. FON-H52H4) immobilized on CM5 Chip can bind Human latent GDF-8, His Tag (Cat. No. GD8-H5243) with an affinity constant of 364 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
The purity of Human latent GDF-8, His Tag (Cat. No. GD8-H5243) is more than 90% and the molecular weight of this protein is around 80-95 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Domagrozumab | PF-6252616; PF-06252616 | Pfizer Inc | Details | ||
| AAV1-FS344 | AAV1-Follistatin; AAV1-FS344 | Phase 2 Clinical | Nationwide Children'S Hospital | Myositis, Inclusion Body; Muscular Dystrophy, Duchenne | Details |
| RO-7204239 | GYM-329; RO-7204239; RG-6237; RG-70240 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co Ltd | Muscular Dystrophy, Facioscapulohumeral; Muscular Atrophy, Spinal | Details |
| Apitegromab | SRK-015 | Phase 3 Clinical | Scholar Rock | Spinal Muscular Atrophies of Childhood; Neuromuscular Manifestations; Muscular Atrophy; Neuromuscular Diseases; Muscular Atrophy, Spinal; Atrophy | Details |
| Talditercept alfa | RO-7239361; BMS-986089; RG-6206; BHV-2000 | Phase 3 Clinical | Bristol-Myers Squibb Company | Muscular Dystrophy, Duchenne; Neuromuscular Diseases; Muscular Atrophy, Spinal | Details |
This web search service is supported by Google Inc.
A-Z
